Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus.
about
Oncolytic viruses as therapeutic cancer vaccinesOncolytic viruses as immunotherapy: progress and remaining challengesReplication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical DataVesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancerChikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the BrainOncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future PerspectivesThe strength of the T cell response against a surrogate tumor antigen induced by oncolytic VSV therapy does not correlate with tumor controlFunctional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse.Mathematical model for radial expansion and conflation of intratumoral infectious centers predicts curative oncolytic virotherapy parameters.The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical site.Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent.Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation.The Effect of Vector Silencing during Picornavirus Vaccination against Experimental Melanoma and GliomaAdoptive transfer of cytotoxic T lymphocytes targeting two different antigens limits antigen loss and tumor escapeThe efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated miceMurine Tumor Models for Oncolytic Rhabdo-Virotherapy.Ovarian cancer treatment with a tumor-targeting and gene expression-controllable lipoplexDefinitive Management of Oligometastatic Melanoma in a Murine Model Using Combined Ablative Radiation Therapy and Viral ImmunotherapyOncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenocarcinoma.Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence.Replicating viral vectors for cancer therapy: strategies to synergize with host immune responses.Evolution of oncolytic viruses: novel strategies for cancer treatment.Oncolytic virus-mediated reversal of impaired tumor antigen presentation.Sorting Out Pandora's Box: Discerning the Dynamic Roles of Liver Microenvironment in Oncolytic Virus Therapy for Hepatocellular Carcinoma.Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways.The role of oncolytic virus immunotherapies to subvert cancer immune evasion.Intratumoral immunotherapy for melanoma.Lassa-vesicular stomatitis chimeric virus safely destroys brain tumorsInhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy.Oncolytic Virotherapy: A Contest between Apples and Oranges.Sharpening the Edge for Precision Cancer Immunotherapy: Targeting Tumor Antigens through Oncolytic Vaccines.Highly attenuated recombinant vesicular stomatitis virus VSV-12'GFP displays immunogenic and oncolytic activitySystemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer.Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence.Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a "Hammer" and "Anvil".Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies.Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPVPOS Cancers.
P2860
Q21245758-64FCBE1B-554C-4D07-B667-81BF229C99C9Q26745942-E8563B79-3B4D-451B-96DD-AF125568F3BCQ26801501-35383AAD-0E0A-4000-8D72-821DF820DB3FQ27021839-34424ECF-E088-4C05-8866-3A5C9F6FC7D2Q28223031-98D10598-5179-404E-B7F0-137A7B0474F1Q33679505-3B2CBF7E-AA72-4E34-9D81-12AB175A4343Q33724224-F01C7AE3-7B69-4A57-AF58-5869F40AB2DAQ34764685-94E0CBA7-F08C-4499-9A90-2C07FD21CC2BQ34989252-9578784C-F7BE-4A6B-BD46-B9C57A8D705FQ35212733-907B9309-0D03-4C43-A056-58097B74F153Q35275179-ACE7B042-4A9D-4C91-AA04-89B783722592Q35531563-3BFA532E-A591-4D41-9067-1A3676D55329Q36112877-5009372A-114A-4903-B1C7-C7C2D165A1FDQ36321054-3592C85D-1B01-42AC-9120-7C61BDC84891Q36673729-713FAC32-5920-4117-977C-939FC8D34090Q36751597-5FCF9721-AC6E-4179-9773-BE855A709ECDQ36776863-74CA932F-C512-4067-9CA1-BD859713FB0CQ36928875-EFC29542-2692-4D18-97C6-5292D3283275Q37123143-1A35A9EF-7ADB-46DC-9277-B4B4780FA9C9Q37477557-2A881214-2FA2-4384-9EFE-51FFEB094A61Q37933439-DA3067C9-97DE-4AF1-BE11-1716D35D2EE4Q38159802-6F88B885-AC7F-4136-AF64-C8DDB6EDA816Q38208315-0E146D08-50D7-4FF6-96AE-4BC1E51F206DQ38209337-07370D63-CAE1-434B-8CD3-61C5468397FEQ38223419-03009E97-C8D1-4129-933D-925A7CD2F509Q38286116-49C2468D-60B3-4BAD-9E9E-01ABBEF64030Q38357137-5AC58D95-B211-4D1A-BF97-838E1709E64EQ38518518-0F38F490-2A41-49BA-9ABB-7195C804CB98Q38886667-A7E4026C-7021-445E-977D-FEA5A2354DB1Q38941936-89C9F03A-0A10-410F-95EC-F896D2AAFD49Q39230055-37F69799-C277-4734-AB0C-FC557B59FC32Q40104793-464CE12F-3A91-481D-9250-C0C1EF5A0B9AQ41770092-492A3F68-882C-4D9D-A80B-273DBAE289C2Q41875584-1D0F6E36-B684-4A1E-AE9F-BAB72D49E842Q47781149-F5F62EC3-BFD2-47FB-BB13-2F01FC94C036Q54378300-FB29BB68-4AC6-4BE0-BD94-F01321616AD6Q55085319-D351A2A8-7C84-4AC4-BC62-26F866F5AD19Q55652233-8268FD18-9623-4772-8BC0-82E3813C82E7
P2860
Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Activating systemic T-cell imm ...... th vesicular stomatitis virus.
@ast
Activating systemic T-cell imm ...... th vesicular stomatitis virus.
@en
Activating systemic T-cell imm ...... th vesicular stomatitis virus.
@en-gb
type
label
Activating systemic T-cell imm ...... th vesicular stomatitis virus.
@ast
Activating systemic T-cell imm ...... th vesicular stomatitis virus.
@en
Activating systemic T-cell imm ...... th vesicular stomatitis virus.
@en-gb
prefLabel
Activating systemic T-cell imm ...... th vesicular stomatitis virus.
@ast
Activating systemic T-cell imm ...... th vesicular stomatitis virus.
@en
Activating systemic T-cell imm ...... th vesicular stomatitis virus.
@en-gb
P2093
P2860
P356
P1433
P1476
Activating systemic T-cell imm ...... th vesicular stomatitis virus.
@en
P2093
Christine Pulido
Diana Rommelfanger
Jill Thompson
Karen Kaluza
Phonphimon Wongthida
Richard Vile
Rosa Maria Diaz
Timothy Kottke
P2860
P304
P356
10.1089/HUM.2010.216
P577
2011-04-11T00:00:00Z